Skip to main content

News of Note—Johnson & Johnson, Bavarian Nordic and more

In this week's news of note, Johnson & Johnson announced a data publication for its "mosaic-based" HIV vaccine. (Pixabay)

Here is some other vaccine news of note for the week:

> Johnson & Johnson announced that The Lancet published data from its phase 1/2b study of a "mosaic-based" HIV vaccine. The company advanced the shot to an efficacy test last November. Release | FiercePharma article

> Bavarian Nordic announced that a phase 2 trial of the company's cancer vaccine CV301 and Bristol-Myers Squibb's Opdivo started in patients with resectable hepatic-limited metastatic colorectal cancer. Release


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> MabVax licensed an antibody development program for multiple cancers to Boehringer Ingelheim for $11 million upfront, plus undisclosed milestones. Release

> Even though Neovacs' therapeutic lupus vaccine missed a primary efficacy endpoint in a phase 2b study, the company is moving into phase 3 based on other results. Release

> Altimmune named Mitchel Sayare, Ph.D., its executive chairman and José Ochoa its chief business officer. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.